Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06953726 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparing the Safety and Efficacy of Apixaban and Rivaroxaban

Study acronym: VALIANT-AF-T
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 5 → 9 locations Eligibility criteria expanded, about 11 words · Secondary endpoints: details revised at 1 of 5 entries · Study description expanded, about 19 words Show 3 more changesShow less
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Study description expanded, about 19 words
  2. Recruitment opened Trial sites expanded: 1 → 5 locationsv4 Show 1 more changeShow less
    • Trial sites expanded: 1 → 5 locations
  3. Start date: Mar 30, 2026 to Jun 1, 2026 Eligibility criteria expanded, about 50 words · Study description expanded, about 62 wordsv3 Show 2 more changesShow less
    • Eligibility criteria expanded, about 50 words
    • Study description expanded, about 62 words

    See this version in full on ClinicalTrials.gov ↗

  4. Start date: Jun 2, 2025 to Mar 30, 2026 Secondary endpoints revised (5)v2 Show 1 more changeShow less
    • Secondary endpoints revised (5)

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
* The trial will compare two anticoagulants ("blood thinners") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation. The two most commonly-used anticoagulants will be compared: apixaban (Eliquis) and rivaroxaban (Xarelto). They are considered by many doctors to have similar benefits and risks, but no one knows for sure. * The trial only enrolls patients with a diagnosis of atrial fibrillation ("A Fib") or atrial flutter. Most participants will be age 65 or older, and should already be taking apixaban or rivaroxaban. * The investigators will measure, in about 10,000 VA patients nationally, whether the rates of stroke, major bleeding, or death differ between these two drugs. * The trial will last about 7 years, but after the first prescription, all information will be collected from electronic medical records.
Trial Details
NCT Number NCT06953726
Lead Sponsor VA Office of Research and Development
Collaborators: Food and Drug Administration (FDA)
Conditions Atrial Fibrillation
Enrollment 10,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov